Skip to main content

and
  1. Article

    Open Access

    Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis

    One target of rheumatoid arthritis (RA) treatment is to achieve early sustained remission; over the long term, patients in sustained remission have less structural joint damage and physical disability. We eval...

    Paul Emery, Yoshiya Tanaka, Vivian P. Bykerk in Rheumatology and Therapy (2023)

  2. Article

    Open Access

    HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA

    Certain risk alleles associated with autoantibody-positive rheumatoid arthritis (RA) have been linked to poorer prognoses. In patients with autoantibody-positive RA, abatacept shows differential efficacy to tu...

    William Rigby, Jane H. Buckner, S. Louis Bridges Jr in Arthritis Research & Therapy (2021)

  3. No Access

    Article

    Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis

    Juvenile idiopathic arthritis (JIA) encompasses several forms of chronic inflammatory arthritis of unknown etiology presenting in children < 16 years of age, with a minimum symptom duration of 6 weeks. Approxi...

    Hermine I. Brunner, Robert Wong, Marleen Nys, Tzuyung D. Kou in Pediatric Drugs (2020)

  4. Article

    Open Access

    Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2–5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept

    Patients with polyarticular-course juvenile idiopathic arthritis (pJIA), receiving disease-modifying anti-rheumatic drugs with immunosuppressive effects, may be at increased risk of vaccine-preventable infecti...

    Hermine I. Brunner, Nikolay Tzaribachev, Gabriel Vega Cornejo in Pediatric Rheumatology (2020)